Randomized study of the efficacy of monoclonal antibodies in patients with refractory psoriasis

Abstract

BACKGROUND: The main vector of psoriasis therapy is suppression of proliferative activity of keratinocytes, normalization of their differentiation, neutralization of immune inflammation in the dermis and normalization of cytokine balance.

AIM: of the study was to study the efficacy and tolerability of an IL-17A inhibitor (secukinumab) as monotherapy and in combination with methotrexate in patients with moderate and severe psoriasis vulgaris.

MATERIALS AND METHODS: The severity of psoriasis was assessed by the Psoriasis Prevalence and Severity Index (Psoriasis Area and Severity Index, PASI). To assess the damage to the nail plates of the hands and feet in psoriasis, the NAPSI index (Nail Psoriasis Severity Index) was used. In order to assess the quality of life of patients with psoriasis, a Russian-language version of the dermatological quality of life index (DQLI) was used. Patients' quality of life was assessed before the prescribed therapy and at 12 weeks of treatment. Assessment of the severity of itching and its impact on the daily life of patients was carried out according to the Prurindex questionnaire.

RESULTS: All patients were divided into two groups by a randomized method. The first group included 25 patients who received therapy with secukinumab in the age category of 55 (30–67) years. The second group included 25 patients aged 56 (34–69) years of moderate and severe psoriasis who were treated with secukinumab after initiation (300 mg) 150 mg subcutaneously in combination with methotrexate 15 mg intramuscularly for 24 weeks. Thus, in the first group PASI 90 was achieved after 24 weeks ― in 69%, PASI 100 ― in 31% patients; in the second group ― PASI 90 ― in 68%, PASI 100 ― in 32% patients respectively. In both groups, it was possible to maintain clinical remission (PASI ≥90) in 87.3% of patients throughout the year. During therapy in patients of both groups, there was a decrease in DLQI values from 25.6±3.7 to 3.5±3.1 (p <0.01) in the first group and from 23.3±3.7 up to 3.1±2.6 in the second group.

CONCLUSIONS: Treatment of patients with moderate and severe psoriasis vulgaris with secukinumab has shown its high efficacy and safety. Moreover, it was estimated that the combination of secukinumab and methotrexate is comparable in effectiveness to secukinumab monotherapy. It has been established that the use of secukinumab as monotherapy and in combination with methotrexate significantly improves the quality of life of patients with moderate and severe psoriasis vulgaris.

Keywords

secukinumab / methotrexate / psoriasis vulgaris / monoclonal antibody

References

[1] Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Psoriasis in special localizations. Reumatologia. 2018;56(6):392–398. doi: 10.5114/reum.2018.80718

[2] Sobolewski P., Błaszczak A., Szymańska E., Walecka I. Psoriasis in special localizations // Reumatologia. 2018. Vol. 56, N 6. Р. 392–398. doi: 10.5114/reum.2018.80718

[3] Kubanov AA, Bogdanova EV. The results of the activities of medical organizations providing medical care in the field of dermatovenerology in 2020: Work in a pandemic. Bulletin Dermatology Venereology. 2021;(4):8–32. (In Russ). doi: 10.25208/vdv1261

[4] Кубанов А.А., Богданова Е.В. Итоги деятельности медицинских организаций, оказывающих медицинскую помощь по профилю дерматовенерология, в 2020 году: работа в условиях пандемии // Вестник дерматологии и венерологии. 2021. № 4. С. 8–32. doi: 10.25208/vdv1261

[5] Olisova OY, Garanyan LG. Epidemiology, etiopathogenesis and comorbidity in psoriasis: new facts. Russ J Skin Venereal Diseases. 2017;20(4):214–219. (In Russ). doi: 10.18821/1560-9588-2017-20-4-214-219

[6] Олисова О.Ю., Гаранян Л.Г. Эпидемиология, этиопатогенез и коморбидность при псориазе ― новые факты // Российский журнал кожных и венерических болезней. 2017. Т. 20, № 4. С. 214–219. doi: 10.18821/1560-9588-2017-20-4-214-219

[7] Chang YT, Chen TJ, Liu PC, et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol. 2009;89(3):262–266. doi: 10.2340/00015555-0642

[8] Chang Y.T., Chen T.J., Liu P.C., et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan // Acta Derm Venereol. 2009. Vol. 89, N 3. Р. 262–266. doi: 10.2340/00015555-0642

[9] Parisi R, Iskandar IY, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. Bmj. 2020:(369):m1590. doi: 10.1136/bmj.m1590

[10] Parisi R., Iskandar I.Y., Kontopantelis E., et al. National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study // Bmj. 2020. N 369. Р. m1590. doi: 10.1136/bmj.m1590

[11] Rojas M, Restrepo-Jiménez P, Monsalve DM, et al. Molecular mimicry and autoimmunity. J Autoimmunity. 2018;(95):100–123. doi: 10.1016/j.jaut.2018.10.012

[12] Rojas M., Restrepo-Jiménez P., Monsalve D.M., et al. Molecular mimicry and autoimmunity // J Autoimmunity. 2018. N 95. Р. 100–123. doi: 10.1016/j.jaut.2018.10.012

[13] Parkhouse AR. Experiences of stigma-stress among people living with psoriasis in the United States. Am J Health Behav. 2019;43(2):243–257. doi: 10.5993/ajhb.43.2.2

[14] Parkhouse A.R. Experiences of stigma-stress among people living with psoriasis in the United States // Am J Health Behav. 2019. Vol. 43, N 2. Р. 243–257. doi: 10.5993/ajhb.43.2.2

[15] Danielsen K. Increased risk of death in patients with psoriasis: Disease or lifestyle? Br J Dermatol. 2019;180(1):3–4. doi: 10.1111/bjd.17141

[16] Danielsen K. Increased risk of death in patients with psoriasis: Disease or lifestyle? // Br J Dermatol. 2019. Vol. 180, N 1. Р. 3–4. doi: 10.1111/bjd.17141

[17] Pilon D, Teeple A, Zhdanava M, et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ. 2019;22(2):196–203. doi: 10.1080/13696998.2018.1557201

[18] Pilon D., Teeple A., Zhdanava M., et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States // J Med Econ. 2019. Vol. 22, N 2. Р. 196–203. doi: 10.1080/13696998.2018.1557201

[19] Kvist-Hansen A, Kaiser H, Skov L, Hansen PR. [Comorbidity in connection with psoriasis is more than psoriatic arthritis]. Ugeskr Laeger. 2018;180(2):V07170526. (In Danish).

[20] Kvist-Hansen A., Kaiser H., Skov L., Hansen P.R. [Comorbidity in connection with psoriasis is more than psoriatic arthritis] // Ugeskr Laeger. 2018. Vol. 180, N 2. Р. V07170526. Danish.

[21] Pilon D, Teeple A, Zhdanava M, et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ. 2019;22(2):196–203. doi: 10.1080/13696998.2018.1557201

[22] Pilon D., Teeple A., Zhdanava M., et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States // J Med Econ. 2019. Vol. 22, N 2. Р. 196–203. doi: 10.1080/13696998.2018.1557201

[23] Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi: 10.1056/nejmoa1314258

[24] Langley R.G., Elewski B.E., Lebwohl M., et al. Secukinumab in plaque psoriasis-results of two phase 3 trials // N Engl J Med. 2014. Vol. 371, N 4. Р. 326–338. doi: 10.1056/nejmoa1314258

[25] Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. doi: 10.1056/nejmoa1503824

[26] Lebwohl M., Strober B., Menter A., et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis // N Engl J Med. 2015. Vol. 373, N 14. Р. 1318–1328. doi: 10.1056/nejmoa1503824

[27] Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet Lond Engl. 2008;371(9625):1665–1674. doi: 10.1016/s0140-6736(08)60725-4

[28] Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) // Lancet Lond Engl. 2008. Vol. 371, N 9625. Р. 1665–1674. doi: 10.1016/s0140-6736(08)60725-4

[29] Marzano AV, Derlino F, Berti EF. Pathogenesis of psoriasis: Focus on autoinflammation. Dermatopathology. 2018;5(1):14–15. doi: 10.1159/000486304

[30] Marzano A.V., Derlino F., Berti E.F. Pathogenesis of psoriasis: Focus on autoinflammation // Dermatopathology. 2018. Vol. 5, N 1. Р. 14–15. doi: 10.1159/000486304

RIGHTS & PERMISSIONS

Olisova O.Y., Nikuradze V.O., Grekova E.V.